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A novel folate-targeted gold-based nanosystem for achieving selectivity towards folate receptor (FR) positive cells is proposed, by
virtue of the fact that the FR is a molecularly targeted entity overexpressed in a wide spectrum of solid tumors. A new inulin-folate
derivative (INU-FA) has been synthesized to act as coating agent for 40 nm gold nanoparticles. The obtained polymer-coated gold
nanoparticles (Au@INU-FA) were characterized in terms of hydrodynamic radius, shape, zeta potential, and aqueous stability and
were loaded with doxorubicin (Au@INU-FA/Doxo). Its release capability was tested in different release media. The selectivity of
Au@INU-FA/Doxo system towards FRs-positive cancer cells was proved by the differences in the quantitative uptake using human
breast cancer MCF7 as FR-positive cells and 16HBE epithelial as noncancer cell line. Furthermore, the folate-mediated uptake
mechanism was studied by FRs-blocking experiments. On the whole Au@INU-FA/Doxo was able to be preferentially internalized
into MCF7 cells proving a folate-mediated endocytosis mechanism which allowed a higher and selective cytotoxic effect towards
cancer cells.The cytotoxicity profile was evaluated on both cancer and noncancer cell lines, displaying that folate-mediated targeting
implied advantageous therapeutic effects, such as amplified drug uptake and increased anticancer activity towards MCF7 cancer
cells.
1. Introduction
Cancer is one of the most important human diseases, being
the leading cause of mortality in the modern world, and
therefore has received significant attention focused on find-
ing new therapeutics [1]. Conventional therapy methods in
cancer, such as chemotherapy, radiation, and surgery, involve
the employment of agents that do not greatly differentiate
between cancerous and normal cells, leading to systemic
toxicity and severe side effects. As a matter of fact, the
effectiveness of many anticancer drugs is limited due to the
inability to reach the target site in sufficient concentration and
to efficiently exert the pharmacological effect without causing
irreversible unwanted injury to healthy tissues and cells [2]. In
contrast to conventional approaches, nanotechnologies may
offer a less-invasive alternative, based on the development of
nanoscale tumor-targeted delivery systems that allow tumor-
selective drug delivery by both passive and active targeting
[3], thus reducing nonspecific cytotoxicity and enhancing the
life expectancy and quality of life of the patient [4]. Molec-
ularly targeted therapy emerged as an effective approach to
overcome the lack of specificity of conventional chemother-
apeutic agents [5]. Different nanostructured drug delivery
systems using a variety of engineered materials including
polymers (polymeric nanoparticles, micelles, or dendrimers)
[6–8], lipids (liposomes) [9], viruses (viral nanoparticles)
[10], organometallic compounds, and metallic nanoparticles
have been developed [11]. Among these, gold nanoparticles
(GNPs) have emerged as promising carriers for drug delivery
applications. In particular, GNPs offer several advantages
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for biomedicine being versatile agents with unique optical
(Surface Plasmon Resonance; SPR) and physicochemical
properties [12]. They have been extensively used as drug
delivery systems and as highly sensitive diagnostic tools as
well as hyperthermia agents depending on their tunable
shape, size, and composition. Recently, the preparation of
polymer-functionalized GNPs has attracted increasing inter-
est not only to improve the stability of nanoparticles in
physiological media but also to modify the surface properties
of nanoparticles. For example, bioconjugation of GNPs with
targeting groups for active tumor targeting has been achieved
due to the high binding affinity of gold for thiol groups [13].
Moreover, in vivo applications of GNPs require poly-
meric coatings to ensure high physicochemical stability and
biocompatibility. A wide variety of biocompatible polymers
that might perform these coating functions have been inves-
tigated, including natural and synthetic polymers [14, 15].
The coating polymers must satisfy some requirements such
as ensuring long-term stability of GNPs in aqueous media
and preventing their aggregation in different body districts.
Moreover coated GNPs should guarantee a prolonged blood
circulation time and provide active functional groups useful
to conjugate targeting ligands to GNPs surface. Our group
has synthetized many polymeric materials that may be used
to coatmetallic nanoparticles, including synthetic polyamino
acid derivatives [16] and polysaccharides based constructs
[17, 18]. Among them, inulin, a natural, biocompatible, and
biodegradable polysaccharide consisting of linear chains of
𝛽-(2-1) fructose units that exhibit many hydroxyl functional
groups that make inulin versatile and easy to functionalize,
has been employed as coating agent for metal NPs and
used in several biomedical applications [17–24]. One of
the strategies to achieve cancer specificity is to conjugate
targeting ligands to the polymeric coating of GNPs. Then,
the targetingmolecule should be able to recognize and bind a
specific receptor on the target cell surface to induce selective
internalization of the system. Among targeting ligands, there
is the vitamin folic acid (FA). Folate receptors (FRs) are selec-
tively overexpressed on a wide spectrum of human cancer
cells. Moreover, FA has a low molecular weight (Mr 441.4),
high receptor affinity (𝐾𝑑 ≈ 10
−10M), low immunogenicity,
stability during storage, ease of modification, compatibility
with a variety of organic and aqueous solvents, and low cost
and is readily available [25, 26]. For example, in a recent work
carried out by Banu et al. gold nanoparticles loaded with dox-
orubicin have been functionalized with folic acid to achieve
selectivity towards MDA-MB-231 breast cancer cells [27].
In this work folic acid was chemically conjugated via
amide bond to the backbone of an inulin amino-derivative.
Taking advantage of the well-known chemical reactivity of
thiol and amino groups with gold surfaces, the new inulin-
folate conjugate derivative, INU-FA, was used to successfully
functionalize the surface of 40 nm gold nanospheres. In
particular, the interactions between the available amino
pendant groups of INU-FA and gold nanoparticles were
exploited to stabilize gold nanoparticles. Although thiol
groups have a stronger affinity to the gold particles sur-
face compared to amino groups, from a synthetic point of
view, the experimental conditions of amino-functionalized
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Figure 1: Schematic illustration of the selective cytotoxic effect of
Au@INU-FA/Doxo on MCF7 cancer cells, expressing high levels of
FRs, comparedwith normal human bronchial epithelial cells 16HBE.
copolymers are more advantageous than thiolated polymers,
not being necessary complicated experimental procedures
such as the precise control of pH of the reaction and the
total absence of oxygen in the reaction environment to avoid
disulfur formation and, as a consequence, polymer crosslink.
As additional advantage, amino-functionalized copolymers
are endowed with a long-term stability, maintaining their
chemical characteristics unaltered.
The obtained system, henceforth named Au@INU-FA/
Doxo, was able to load doxorubicin while showing excel-
lent physiochemical stability. By using blocking receptors
experiments we demonstrated the folate-mediated uptake of
Au@INU-FA/Doxo into FRs-positive human breast cancer
cells MCF7 (Figure 1). Moreover we proved that the conju-
gation of folate onto inulin backbone enhanced the selective
drug accumulation into MCF7 cells, expressing high levels of
FRs, compared with normal human bronchial epithelial cells
(16HBE), thereby resulting in a marked higher cytotoxicity
towards cancer cells.
2. Materials and Methods
2.1. Materials. Inulin-2-aminoethyl-carbamate (INU-EDA),
used as a starting copolymer, was synthetized as previ-
ously reported [24]. Inulin, ethylenediamine (EDA), bis(4-
nitrophenyl)carbonate (BNPC), gold chloride trihydrate
(HAuCl4 3H2O), sodium citrate tribasic dihydrate, N-
ethyl-N󸀠-(3-dimethylaminopropyl)carbodiimide hydrochlo-
ride (EDC-HCl), N-hydroxysuccinimide (NHS), and bicin-
choninic acid kit for protein determination, were purchased
from Aldrich. Sephadex G-15 and anhydrous dimethylfor-
mamide (DMF) were purchased from Fluka (Switzerland).
All reagents were of analytic grade, unless otherwise stated.
The 1H NMR spectra were recorded using a Bruker Avance
II 300, spectrometer operating at 300MHz. Size exclusion
chromatography (SEC) was carried out using a Phenomenex
PolySep-GFC-P3000 column (California, USA) connected
to a Waters 2410 refractive index detector. DMF + LiBr
0.1% solution was used as an eluent at 60∘C with a
flow rate of 0.6mLmin−1, sample concentration 2.5mg/mL.
Poly(ethylene oxide) standards (range 10–1.5 kDa) were used
to set up calibration curve.
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2.2. Synthesis of Gold Nanoparticles GNPs (Au@citrate). Cit-
rate stabilized 40 nm GNPs with a spherical shape and a
narrow size distribution were synthetized via the reduction
of HAuCL4 by sodium citrate [28].
2.3. Synthesis of INU-EDA-Folate Copolymer (INU-FA).
Inulin-2-aminoethyl-carbamate (INU-EDA), with a deriva-
tization degree of pendant primary amine groups (DDEDA)
of 25mol% related to inulin monomeric units was used
as starting copolymer [20]. A proper amount of folic acid
(143.9mg, 0.326mmol) was solubilized in Milli-Q water at
pH 7.02, and then NHS (56.24mg, 0.488mmol) and EDC-
HCl (93.68 g, 4.88mmol) powders were added to the reactive
mixture adjusting the pH at 7.02. The resulting solution was
added to 2mL of a INU-EDA solution in Milli-Q water
(200mg, 1.086mmol of amino pendant groups) drop-wise
and left to react at 25∘C for 18 h. The INU-FA conjugate
was then purified by gel filtration chromatography using
Sephadex G-15 as separating gel. Then the INU-FA solution
was freeze-dried from water; the pure product was obtained
with 88% w/w yield based on the starting inulin (176mg of
INU-FA product starting from 200mg of the starting inulin).
Size exclusion chromatography (SEC): Mw 6784, Mw/Mn
1.24. 1H NMR (300MHz, D2O): 𝛿 2.90–3.40 (4HEDA, -NH-
CH2-CH2-NH2), 3.60–3.90 (5HINU, -CH2-OH; -CH-CH2-
OH; -C-CH2-O-), 3.92–4.30 (2HINU, -C-CH-OH; -CH-OH),
𝛿 7.517–6.685 (4HFA, phenyl group).
2.4. Preparation of INU-FA and INU-FA/Doxo Function-
alized GNPs. A solution of INU-FA copolymer (952.5𝜇L,
250𝜇g/mL), treated with 2𝜇L of TEA, was added to the
citrate capped GNPs (Au@citrate), at a ratio of 10 INU-
EDA-FA/Au nm2. The mixture was incubated for 30min
at room temperature. Coated particles (Au@INU-FA) were
then washed twice by centrifugation at 2760 g (20min,
25∘C) and stored at 4∘C as colloidal dispersion (150 𝜇g/mL
Au0). In these conditions, INU-FA coated nanoparticles
maintain their physical-chemical properties unaltered for at
least six months. For the preparation of doxorubicin loaded
GNPs (Au@INU-FA/Doxo), 60𝜇L of an aqueous doxoru-
bicin hydrochloride solution 1mg/mL, previously treated
with TEA (1𝜇L, 0.7 × 10−2mmol), was added to INU-FA
solution (423 𝜇L, 250 𝜇g/mL). The obtained mixture was
added to 1mL 0.240mg/mL of Au@citrate aqueous disper-
sion to obtain an R Au0/Doxo equal to 4 w/w. After the
incubation time (overnight, room temperature) the system
was centrifuged (20min, at 3.500 rpm) and washed twice
in Milli-Q water to remove the excess of doxorubicin.
Dynamic light scattering (DLS) data is as follows: Au@INU-
FA: 𝑍 average 45.05 nm, PDI 0.14 and 𝑍 potential −11.2mV;
Doxo/Au@INU-FA: 𝑍 average: 40.7 nm, PDI 0.21, and Zeta
potential: −10.7mV.
2.5. Determination of Drug Payload into Au@INU-FA/Doxo
and Drug Release Studies. The amount of drug payload
into Au@INU-FA/Doxo was measured by HPLC method.
A precise amount of Au@INU-FA/Doxo was dispersed in
Milli-Q water pH 4.5/ethanol 2 : 1 (v/v) to extract the loaded
drug. After 2 h of extraction under stirring, the dispersion
was centrifuged (20min, at 3.5000 rpm) and the supernatant
was freeze-dried. Then the solid residue of the extracted
drug was solubilized in the eluent used for HPLC analysis
((NH4)2HPO4 0.4M/Acetonitrile 68 : 32 v/v), filtered on a
cellulose regenerated filter, cut-off 0.2𝜇m, and injected in a
C18 Gemini HPLC column.The content of drug loaded (DL)
into the system was calculated by using a calibration curve
obtained for serially diluted concentrations of doxorubicin in
the eluent and expressed as the amount of loaded doxorubicin
per unit mass of Au0. The DL resulted to be 18 ± 2%
(w/w), while the encapsulation efficiency was calculated to be
93 ± 2%. For drug release studies, an appropriate amount of
Au@INU-FA/Doxo was placed in a dialysis membrane with
a molecular weight cut-off of 12 KDa, immersed in 10mL
of PBS at pH 7.4 and incubated at 37∘C under continuous
stirring. At scheduled time intervals, aliquots of external
medium (1mL) were withdrawn and replaced with an equal
amount of fresh medium. The withdrawn samples were
analyzed by HPLC to determine the amount of released drug.
Release profiles were determined by comparing the amount
of released drug as a function of incubation time with the
total amount of drug loaded into the Au@INU-FA/Doxo.The
same analysis was carried out using PBS pH 5.5 and all the
release data were compared with the diffusion of doxorubicin
alone (free base), obtained by using the same procedure.
Data were corrected taking into account the dilution proce-
dure.
2.6. Transmission Electron Microscopy (TEM). GNPs were
visualized using a TEM JEOL JEM-1400PLUS 120 kV TEM
(Japan) equipped with GATAN US1000 CCD camera (2k
× 2k). 10 𝜇L droplets of the sample were drop casted onto
a piece of ultrathin Formvar-coated 200-mesh copper grid
(Ted.pella, Inc) and left to dry in air.
2.7. UV-Vis Spectroscopy. UV-Visible spectra were recorded
with a Shimadzu UV-2400 spectrophotometer. All samples
(Au@citrate, Au@INU-FA, and Au@INU-FA/Doxo) were
placed in a cell and spectral analysis was performed in
the 400 to 800 nm range at room temperature. For the
determination of the amount of folic acid linked in INU-
EDA, the absorbance of a weighted amount of INU-FA in
Milli-Q water pH 8 for NaOH 1N at 364 nm was measured
and this value was compared to that of a calibration curve
obtained from standard solutions of folic acid in Milli-Q
water pH 8 forNaOH 1N (concentration range from 0.003125
to 0.1mgmL−1; 𝑅2 = 0.998).
2.8. Dynamic Light Scattering (DLS) Analysis and Zeta Poten-
tial Measurements. DLS studies and zeta potential measure-
ments (mV) were performed at 25∘C using a Malvern Zeta-
sizer Nano ZS instrument, fitted with a 532 nm laser at a fixed
scattering angle of 173∘. Aqueous solutions of Au@citrate,
Au@INU-FA, and Au@INU-FA/Doxo (0.015mg/mL) were
analyzed. The intensity-average hydrodynamic diameter and
polydispersity index (PDI) were obtained by cumulant anal-
ysis of the correlation function. The zeta potential (mV)
was calculated from the electrophoretic mobility using the
Smoluchowski relationship and assuming that 𝐾 ⋅ 𝑎 ≫ 1
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(where𝐾 and 𝑎 are theDebye–Hu¨ckel parameter and particle
radius, resp.).
2.9. Energy Dispersive X-Ray Analysis of the Surface of
Au@INU-FA/Doxo. Qualitative elementary composition of
freeze-dried Au@INU-FA/Doxo was obtained using a scan-
ning electron microscope, ESEM Philips XL30. Samples were
dusted on a double sided adhesive tape previously applied
on a stainless steel stub prior to chemical elementary analy-
sis.
2.10. Cell Cytotoxicity. Human breast cancer cells (MCF7)
and human bronchial epithelial cells (16HBE) cells were
purchased from Istituto Zooprofilattico Sperimentale della
Lombardia e dell’Emilia Romagna (Italy). Cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM, Euro-
clone, Italy) with 10% fetal bovine serum (FBS) and 1% of
penicillin/streptomycin (100U/mL penicillin and 100mg/mL
streptomycin), 1% glutamine, and 0.5% of amphotericin B, at
37∘C in 5% CO2 humidified atmosphere.
The cytotoxicity was assessed by theMTS assay onMCF7
and 16HBE cells using MTS cell proliferation assay (Cell
Titer 96 Aqueous One Solution, Promega, Italy). Cells were
seeded in 96-well plate at a density of 2 × 104 cells/well and
grown as reported above. After overnight attachment, the
medium was replaced with 200 𝜇L/well of fresh cell medium
containing empty Au@INU-FA and Au@INU-FA/Doxo at
a concentration per well equal to 330, 165, 82.5, 41.25, and
20.62𝜇g/mL of Au0, corresponding to 100, 50, 25, 12.5, and
6.125𝜇M of doxorubicin per well. After 4, 24, and 48 h,
supernatants were removed and a 1/20 dilution of MTS
reagent in media was added to the wells (120𝜇L/well) and
incubated at 37∘C for 2 h. Then, the absorbance at 490 nm
wasmeasured using amicroplate reader (Multiskan,Thermo,
UK). Pure cellmediumwas used as a negative control. Results
were expressed as percentage of the control cells. All cul-
ture experiments were performed in triplicate. Doxorubicin
hydrochloride solutions at the same tested concentrations
were used as a positive control.
2.11. Blocking Receptor Experiments. FA receptor (FR) block-
ing assay, followed by MTS assay, was performed on MCF7
as FRs overexpressing cells. A density of 2 × 104 cells per
well, grown with a DMEM without folic acid, were seeded
in a 96-well culture plate. After overnight attachment, the
medium was replaced with 200 𝜇L/well of DMEM supple-
mented with 250mg/L of folic acid to saturate FRs. After
3 h incubation time at 37∘C, the medium was replaced
with 200𝜇L/well of fresh cell medium containing Au@INU-
FA/Doxo at a concentration per well equal to 330, 165, 82.5,
41.25, and 20.62 𝜇g/mL of Au0, corresponding to 100, 50,
25, 12.5, and 6.125 𝜇M of doxorubicin per well. After 4, 24,
and 48 h, supernatants were removed and MTS assay was
carried out as reported above. Pure cell medium was used
as a negative control. Results were expressed as percentage
reduction of the control cells. All culture experiments were
performed in triplicate. Doxorubicin hydrochloride solutions
at the same concentrations were used as a positive con-
trol.
2.12. Au@INU-FA/Doxo Uptake Studies. MCF7 and 16HBE
cell lines were seeded at a density of 2 × 104 cells/well and
grown as reported above. After overnight attachment the
mediumwas replacedwith 200𝜇Lof freshDMEMcontaining
Au@INU-FA/Doxo at the concentration of 12 𝜇g/mL Au0,
corresponding to 5𝜇M of doxorubicin, and cells were incu-
bated for 30 minutes, 1 h, and 2 h. After each incubation
period, the mediumwas removed and the cell monolayer was
washed twice with DPBS and fixed with 4% formaldehyde
for 30min. Subsequently, the formaldehyde solution was
removed, the cells were washed with DPBS, and the nuclei
were stained with 4󸀠,6-diamidino-2-phenylindole (DAPI).
After 20min incubation, DAPI solution was removed, the
cells were washed three times with DPBS and observed by
an Axio Vert.A1 fluorescence microscope (Zeiss).The images
were recorded using an Axio CamMRm (Zeiss).
For quantitative Au@INU-FA/Doxo uptake fluorescence
analysis, after incubation, cells were lysed in 50 𝜇L lysis
buffer (1% Triton X-100, 2% SDS in DPBS) at 37∘C. 25 𝜇L
of lysates was transferred to disposable 96-well plates and
diluted to 100 𝜇LwithMilli-Qwater for fluorescence intensity
measurements (𝜆EX: 490 nm; 𝜆EX: 580 nm) on an Eppendorf
plate reader spectrofluorophotometer. The remaining 25𝜇L
of lysates were used to determine the protein content using
the bicinchoninic acid kit for protein determination (Sigma
Aldrich), according to the protocol of the manufacturer. For
determination of the mean fluorescence intensity, fluorescent
signals were corrected for the amount of protein in the
samples. Free Doxorubicin (Doxo HCl) 5 𝜇M was used as
positive control for quantitative uptake fluorescence analysis.
The experiment was carried out in triplicate.
2.13. Statistical Analysis. A 𝑡-test was applied to compare
different sample groups. Data were considered statistically
significant with a value of 𝑝 < 0.05. All values are the average
of three experiments ± standard deviation.
3. Results and Discussions
3.1. Synthesis of INU-FA Copolymer. Unregulated prolifera-
tion of cancer cells requires high consumption of folate for
DNA replication, leading to a folate receptor (FR) overex-
pression in cancers like breast, ovary, uterus, colon, lung, and
kidney cancer. In normal tissues, FRs are present in low or
nondetectable quantities.These features have encouraged the
synthesis of the new folate conjugate of inulin, INU-FA, here
proposed as a coating agent for 40 nm gold nanospheres, in
order to confer FR-mediated endocytosis properties to the
nanosystem and to allow a higher and selective cytotoxic
effect towards cancer cells. First of all, inulin was partially
functionalized with EDA so as to introduce primary amine
pendants that can be utilized as versatile functions allowing
further derivatization. A derivatization degree in EDA of 25%
was obtained (DDEDA related to inulin repeating units). In a
second step, INU-EDAwas functionalized with FA by amidic
bond, using EDC and NHS as coupling agents, as shown
in Scheme 1. The stoichiometric conditions employed were
moles of FA/moles of amino pendant groups in INU-EDA
= 0.3; moles of EDC-HCl/moles of FA = 1.5; and moles of
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Figure 2: 1H NMR spectrum (300MHz, D2O) of INU-FA copoly-
mer. Spectroscopic data are in agreementwith attributed structure: 𝛿
2.72–3.17 (4HEDA, -NH-CH2-CH2-NH2), 3.611–3.704 (5HINU, -CH2-
OH; -CH-CH2-OH; -C-CH2-O-), 3.99–4.12 (2HINU, -C-CH-OH;
-CH-OH), 6.68–7.5 (HFA, aromatic ring).
NHS/moles of FA = 1.5. The amount of folic acid linked to
INU-EDA copolymer was measured by using two methods:
1H NMR and UV spectroscopies. The 1H NMR allowed
an easy quantification of the FA molecules linked to inulin
(Figure 2), by comparing the integrals of the peak at 𝛿 7.52–
6.69, ascribable to the protons of the phenyl ring of FA,
to those at 𝛿 3.55–4.19 belonging to the protons of INU
backbone.Themolar percent of FA covalently linked to inulin
(DDFA%) was also determined bymeans of UV spectroscopy,
measuring the absorbance of a weighted amount of INU-
FA in Milli-Q water pH 8 for NaOH 1N at 𝜆 364 nm, and
comparing this value to that of a calibration curve obtained
from standard solutions of folic acid in the same solvent. The
average of FA derivatization degree (DDFA%) calculated by
means of 1H NMR and UV spectroscopies resulted equal to
5.45mol % referred to the inulin repeating units. The INU-
FA conjugate still maintains a large number of primary amine
groups available for the subsequent coating of GNPs trough
covalent bond. Relative weight, average molecular weight
(Mw), and polydispersity of the synthetized copolymers
were determined by SEC analyses and data are reported in
Table 1. The molecular weight increment of INU-EDA and
INU-FA with respect to the starting polymer confirmed the
derivatization of inulin in turn with EDA and FA, although
significant fragmentation of the polymeric backbone was not
observed.
3.2. Preparation and Characterization of INU-FA Coated
GNPs (Au@INU-FA). INU-FA-coated gold particles
(Au@INU-FA) were prepared by means of the chemical
adsorption of folate conjugate derivative of inulin onto
GNPs surface. Taking advantage of the high affinity of gold
for primary amines available in the conjugate backbone, a
C
N
O
AuNa
1.2 2.40.6 1.8
Figure 3: Energy dispersion X-ray chemical analysis of the surface
of Au@INU-FA.
Table 1: Molecular weight (Mw) and polydispersity (Mw/Mn) of
inulin and its parent copolymers.
Copolymers Mw (Mw/Mn)
Inulin 6319 1.27
INU-EDA 6504 1.31
INU-FA 6784 1.24
stable polymeric coating able to confer aqueous stability to
GNPs was obtained. The functionalization of GNPs surface
was accomplished using an organic base (TEA) in such
a manner to completely deprotonate the pendants amino
groups of INU-FA, thus avoiding aggregation phenomena
due to electrostatic interactions between the positive charged
copolymer and the negative stained GNPs [29]. This simple
method overcomes tedious processes that usually involved
PEG as a prestabilizing agent to avoid undesired nanoparticle
aggregation, as previously reported [30]. The aim of this
coating was manifold. On one hand INU-FA may act as a
colloidal hydrophilic coating stabilizing the dispersion of the
nanosystem into aqueous media. Furthermore, it behaves as
a targeting moiety for the cancer-targeted therapy. Finally, it
might increase the loading of the drug by means of physical
interactions.
The presence of polymer coating on GNPs surface was
studied by qualitative energy dispersion X-ray elemental
analysis (Figure 3), which showed the characteristic peaks of
carbon, oxygen, and nitrogen, of the polymeric coating on
GNPs surface.
The stability of the nanosystems in different aqueous
media was studied by UV-Vis spectroscopy. As shown in
Figure 4, a tiny redshift of the LSPR band (∼530 nm) of
Au@INU-FA without broadening was observed (Figure
4(a)), implying the absence of aggregation phenomena of
the starting Au@citrate particles observed in TEM images
(Figure 4(b)), in the whole media tested. Moreover, the UV
profile of the drug-loaded nanosystem, without broadening
in comparison with its parent systems, still confirmed the
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Scheme 1: Synthesis of INU-FA.
absence of aggregation after the drug loading processing, thus
suggesting that doxorubicin was highly adsorbed onto the
nanosystem surface.
DLS measurements supported the results obtained via
UV-Vis spectroscopy, yielding an average hydrodynamic
diameter of about 40 nm (Table 2). The obtained Au@INU-
FA nanoparticles, stabilized by the folate-inulin derivative,
were able to load a suitable amount of the anticancer
drug doxorubicin. Doxorubicin was selected as anticancer
drug widely employed to treat leukemia and Hodgkin’s
lymphoma, as well as cancers of the bladder, breast, stomach,
lung, ovaries, thyroid, soft tissue sarcoma, multiple myeloma,
and others [31]. Drug loading was carried out adding
aqueous INU-FA and doxorubicin hydrochloride solutions,
previously treated with a molar excess of TEA, to the
dispersion of Au@citrate [17, 20]. The drawing forces that
allowed the loading of doxorubicin on Au@INU-FA/Doxo
nanoparticles were both physical and chemical interactions.
In particular, the weakly bound component is attributed to
the formation of an electrostatic complex between protonated
amine molecules of doxorubicin and surface-bound AuCl4-
/AuCl2- ions, while the more strongly bound species can
Journal of Nanomaterials 7
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Figure 4: UV-Vis spectra of Au@citrate, Au@INU-EDA, Au@INU-FA, and Au@INU-FA/Doxo nanoparticles (a), showing a sharp LSPR
band and the stability of Au@INU-FA/Doxo in different media: PBS pH 7.4, NaCl 0.9% w/v, and Milli-Q water. TEM images of starting
Au@citrate (b).
Table 2: DLS data, zeta potential values, and drug loading % of Au@citrate, Au@INU-FA, and Au@INU-FA/Doxo samples in Milli-Q water
(0.1mg Au0/mL).
Sample 𝑍 average(nm) PDI
Zeta potential
(mV)
Drug loading %
(w/w) evaluated by
HPLC method
Encapsulation
efficiency %
(w/w)
Au@citrate 42.1 0.12 −29.1 — —
Au@INU-FA 45.05 0.14 −11.2 — —
Au@INU-FA/Doxo 40.7 0.21 −10.7 18 ± 2 93 ± 2
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Figure 5: Percentage of released doxorubicin from Au@INU-
FA/Doxo NPs over time, incubated in PBS solutions at pH 7.4
and pH 5.5. Doxorubicin not associated with NPs, in the free base
(-NH2) form, was used to determine normal doxorubicin release
during dialysis.
be assigned to a complex of the form [AuCl(NH2R)] [32].
Moreover, doxorubicin might interact somehow with the
polymer backbone and with the aromatic rings of the folate
groups. The amount of loaded drug, evaluated by HPLC
analysis, was found to be 18% w/w, with an encapsulation
efficacy of approximately 90% (Table 2). DLS measurements
carried out on Au@INU-FA/Doxo showed no significant
variation in size and zeta potential compared to the unloaded
system Au@INU-FA (Table 2).
3.3. Doxorubicin Release Studies. To evaluate the capability
of Au@INU-FA/Doxo to release doxorubicin, release exper-
iments were carried out in two media simulating different
human body districts. In particular, PBS solution at pH 7.4,
whichmimics physiological medium, and pH 5.5, mimicking
endosomal and lysosomal environments, were used. The
release experiments consisted in quantifying the amount of
released doxorubicin in each release media, at fixed time
points. In this experiment the control drug was used as
free base, which is the form used for loading. In Figure 5
the cumulative release of doxorubicin, referred to the total
amount of doxorubicin loaded into nanosystem, is shown as
function of the incubation time. Au@INU-FA/Doxo proved
capable of releasing doxorubicin for a prolonged period of
time and without any initial “burst effect,” for both pH
values. For example, after 48 h, approximately 18% and 23%
of doxorubicin initially loaded in the system were slowly
released in PBS at pH 7.4 and pH 5.5, respectively, indicating
that a slow drug release rate, at both pH values, could be
obtained even after reaching the tumor site [33].
3.4. In Vitro Biological Assays. The tumor-selective folate-
mediated cytotoxicity of the Au@INU-FA/Doxo here pre-
pared was established by MTS assay on human breast cancer
cell line (MCF7) and on human bronchial epithelial cell
line (16 HBE). Cells were exposed to Au@INU-FA and
Au@INU-FA/Doxo, as well as to free doxorubicin, for either
4 h, 24 h, or 72 h at concentrations of 330, 165, 82.5, 41.25,
and 20.62 𝜇g/mL of Au0, corresponding to 100, 50, 25, 12.5,
and 6.125 𝜇M of doxorubicin per well. Actually, Au@INU-
FA resulted without cytotoxic effect and no significant
differences after 4 h, 24 h, and 48 h incubation over the
range of concentrations and time points tested for both cell
lines, indicating an excellent cytocompatibility of the empty
nanosystem even at the higher concentration tested (data
not shown). Differently, free doxorubicin, used as positive
control, resulted highly cytotoxic in both cell lines even at
the lowest tested concentrations (Figure 6(a)) and did not
greatly differentiate between cancer and noncancer cells,
being even much more cytotoxic for 16HBE noncancer cell
line. Interestingly, as shown in Figure 6(b), MCF7 cancer cell
line was significantly more sensitive to the cytotoxic effect of
Au@INU-FA/Doxo compared with epithelial cells over the
three time points tested, as confirmed by the IC50 values
which appear importantly lower for cancer cells (Table 3).
These results can be explained with the ability of the folate-
targeted system to be principally internalized by MCF7 cells,
which express high levels of FRs, rather than in 16HBE
noncancer cells, suggesting a folate-mediated endocytosis
mechanismwhich allowed exerting a selective cytotoxic effect
towards cancer cells.
To validate the hypothesis of a folate-mediated uptake of
Au@INU-FA/Doxo system, a receptor blocking experiment
on MCF7 cells followed by a MTS cell viability assay was
carried out. In particular, MCF7 cells were first exposed to
a high concentration of folic acid (10 nM) to achieve the
saturation of FRs [34] and then incubated with Au@INU-
FA/Doxo NPs at the same time points and concentration
previously tested. Interestingly, the cytotoxic effect observed
on the MCF7 cells with saturated FRs was significantly lower
if compared with the one exhibited on MCF7 cells in the
assay without folic acid pretreatment, as shown in Figure 7
and easily deducible by IC50 values reported in Table 3.
These findings can be explained by a significant enhance-
ment of cell internalization of Au@INU-FA/Doxo when the
FRs are available to bind the folate on targeted-NPs surface,
thus enabling a folate-mediated endocytosis mechanism
and a higher cytotoxic effect. The selectivity of the folate-
targeted system towards FRs-positive cancer cells was further
confirmed by quantitative uptake assay, measuring Doxo
fluorescence intensity in MCF7 and 16 HBE cell lysates
upon treatment with Au@INU-FA/Doxo in cell cultures and
with free Doxo HCl as positive control. As predicted by
cytotoxicity assay, Au@INU-FA/Doxo taking advantage of
the folate-mediated endocytosis was preferentially internal-
ized into cancer cells already after 2 hours of incubation
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Figure 6: Cell cytotoxicity of free Doxo (a) and Au@INU-FA/Doxo NPs (b) on MCF7 and 16HBE cells after 4 h, 24 h, and 48 h of incubation
time.
Table 3: IC50 values at 24 h and 48 h of Au@INU-FA/Doxo on MCF7 and 16HBE cell lines.
Sample IC5024 h (𝜇M) IC5048 h (𝜇M)
Au@INU-FA/Doxo on MCF7 8.08 7.42
Au@INU-FA/Doxo on 16HBE 72.68 47.14
Au@INU-FA/Doxo on MCF7 + FRs blocked 36.75 13.86
Free Doxo on MCF7 15.79 9.41
Free Doxo on 16HBE 22.89 9.60
time, as demonstrated by the significantly higher doxorubicin
amount intoMCF7 with respect to 16HBE cells (Figure 8(b)),
thus enabling a higher and selective cytotoxic effect towards
cancer cells. Instead, free Doxo HCl not entrapped into
nanoparticles, diffuses in both cell types (MCF7 and 16HBE)
being not able to discriminate between cancer and noncancer
cells. Moreover, negligible differences in uptake are visible
between MCF7 with blocked and not blocked FRs. The lack
of selectivity of doxorubicin, when delivered without a NP
carrier, in noncancer cells at such short time points, could
explain doxorubicin’s toxicity towards normal tissues and
cells.
The internalization of Au@INU-FA/Doxo into can-
cer cells was also qualitatively revealed by fluorescence
microscopy of MCF7 cell line (Figure 9). Images obtained
after exposure of cells toNPs for 1/2 h, 1 h, and 2 h showed that
doxorubicin was progressively accumulated in the cytoplasm
of the cells, as a consequence of the Au@INU-FA/Doxo NPs
internalization.
4. Conclusions
In this study, we reported a novel cytocompatible folate-
targeted gold-based nanosystem, namely, Au@INU-FA, that
can easily load doxorubicin while showing excellent physio-
chemical stability. The use of biocompatible and biodegrad-
able inulin-folate conjugate used as coating agent was found
to give two important advantages: an improvement in the
physical stability of the system in physiological mimicking
media, as proved by UV-Vis spectroscopy, and an increased
anticancer activity towards MCF7 cancer cells by means
of folate-mediated uptake. Au@INU-FA/Doxo has proved
capable of loading 18% of doxorubicin guaranteeing a pro-
longed drug release in different simulated media. Finally, the
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Figure 8: Quantitative uptake analysis of free Doxo HCl (a) and Au@INU-FA/Doxo (b) in MCF7 and 16 HBE cell lines after FRs-blocking
experiment (MCF7 + FRs blocked) and without folic acid pretreatment (MCF7; 16 HBE). Incubation times were 30, 60, and 120 minutes.
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Figure 9: Fluorescence microscopy images of MCF7 cells incubated with Au@INU-FA/Doxo. Incubation times were 1/2 h, 1 h, and 2 h.
Doxorubicin is visualized in red; cell nuclei were stained with DAPI (blue). Magnification was 20x.
system exhibited a preferential accumulation into cancer cells
rather than non-cancer cells. We demonstrated differences
in particle uptake between MCF7 cancer and 16HBE non
cancer cell lines. Our findings offer advantageous therapeutic
effects regarding increased anticancer activity and reduced
non-specific cytotoxicity to surrounding healthy tissues,
supporting the possible selection of Au@INU-FA/Doxo as a
promising candidate for future in vivo evaluations.
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